{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:48:31Z","timestamp":1768294111392,"version":"3.49.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1097\/hjh.0000000000002094","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:54:13Z","timestamp":1554684853000},"page":"1757-1767","source":"Crossref","is-referenced-by-count":9,"title":["Effects of blood pressure-lowering drugs in heart failure"],"prefix":"10.1097","volume":"37","author":[{"given":"Ana-Catarina","family":"Pinho-Gomes","sequence":"first","affiliation":[]},{"given":"Luis","family":"Azevedo","sequence":"additional","affiliation":[]},{"given":"Zeinab","family":"Bidel","sequence":"additional","affiliation":[]},{"given":"Milad","family":"Nazarzadeh","sequence":"additional","affiliation":[]},{"given":"Dexter","family":"Canoy","sequence":"additional","affiliation":[]},{"given":"Emma","family":"Copland","sequence":"additional","affiliation":[]},{"given":"Abdul","family":"Salam","sequence":"additional","affiliation":[]},{"given":"Anthony","family":"Rodgers","sequence":"additional","affiliation":[]},{"given":"Dipak","family":"Kotecha","sequence":"additional","affiliation":[]},{"given":"Kazem","family":"Rahimi","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-4-20210227","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/M16-1754","article-title":"Benefits and harms of intensive blood pressure treatment in adults aged 60 years or older: a systematic review and meta-analysis","volume":"166","author":"Weiss","year":"2017","journal-title":"Ann Intern Med"},{"key":"R2-4-20210227","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1161\/CIRCULATIONAHA.108.815944","article-title":"Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of The National Heart, Lung, and Blood Institute","volume":"119","author":"Lee","year":"2009","journal-title":"Circulation"},{"key":"R3-4-20210227","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"},{"key":"R4-4-20210227","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"R5-4-20210227","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ahj.2012.11.004","article-title":"Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial","volume":"165","author":"Ambrosy","year":"2013","journal-title":"Am Heart J"},{"key":"R6-4-20210227","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10741-012-9315-1","article-title":"Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure","volume":"18","author":"Gheorghiade","year":"2013","journal-title":"Heart Fail Rev"},{"key":"R7-4-20210227","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.296.18.2217","article-title":"Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure","volume":"296","author":"Gheorghiade","year":"2006","journal-title":"JAMA"},{"key":"R8-4-20210227","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","article-title":"Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF","volume":"38","author":"Bohm","year":"2017","journal-title":"Eur Heart J"},{"key":"R9-4-20210227","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/HJH.0000000000001720","article-title":"Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis","volume":"36","author":"Xie","year":"2018","journal-title":"J Hypertens"},{"key":"R10-4-20210227","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/HJH.0b013e3280bad9b4","article-title":"Blood pressure-dependent and independent effects of agents that inhibit the renin\u2013angiotensin system","volume":"25","author":"Turnbull","year":"2007","journal-title":"J Hypertens"},{"key":"R11-4-20210227","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1161\/01.CIR.101.7.758","article-title":"Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial","volume":"101","author":"Levine","year":"2000","journal-title":"Circulation"},{"key":"R12-4-20210227","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0002-8703(00)90095-4","article-title":"Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction","volume":"139","author":"Udelson","year":"2000","journal-title":"Am Heart J"},{"key":"R13-4-20210227","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/heartjnl-2017-311652","article-title":"Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"104","author":"Zheng","year":"2018","journal-title":"Heart"},{"key":"R14-4-20210227","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10741-018-9679-y","article-title":"Pharmacological treatments for heart failure with preserved ejection fraction \u2013 a systematic review and indirect comparison","volume":"23","author":"Bonsu","year":"2018","journal-title":"Heart Fail Rev"},{"key":"R15-4-20210227","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.jacc.2008.09.011","article-title":"Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program","volume":"52","author":"Meredith","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R16-4-20210227","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/ejhf.1060","article-title":"Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial","volume":"20","author":"Selvaraj","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"R17-4-20210227","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"R18-4-20210227","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R20-4-20210227","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","article-title":"Aliskiren, enalapril, or aliskiren and enalapril in heart failure","volume":"374","author":"McMurray","year":"2016","journal-title":"N Engl J Med"},{"key":"R21-4-20210227","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijcard.2012.11.051","article-title":"Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese Chronic Heart Failure (J-CHF) study","volume":"164","author":"Okamoto","year":"2013","journal-title":"Int J Cardiol"},{"key":"R22-4-20210227","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"R23-4-20210227","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1023\/B:CARD.0000025756.32499.6f","article-title":"The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN)","volume":"18","author":"Remme","year":"2004","journal-title":"Cardiovasc Drugs Ther"},{"key":"R24-4-20210227","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study","volume":"314","author":"Cohn","year":"1986","journal-title":"N Engl J Med"},{"key":"R25-4-20210227","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3102\/10769986030003261","article-title":"Bias and efficiency of meta-analytic variance estimators in the random-effects model","volume":"30","author":"Viechtbauer","year":"2005","journal-title":"J Educ Behav Stat"},{"key":"R26-4-20210227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Statist Soft"},{"key":"R27-4-20210227","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(05)74355-5","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","author":"Dargie","year":"1999","journal-title":"Lancet"},{"key":"R28-4-20210227","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet"},{"key":"R29-4-20210227","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"R30-4-20210227","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.105.582320","article-title":"Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III","volume":"112","author":"Willenheimer","year":"2005","journal-title":"Circulation"},{"key":"R31-4-20210227","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/eurheartj\/ehu504","article-title":"Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial","volume":"36","author":"Sakata","year":"2015","journal-title":"Eur Heart J"},{"key":"R32-4-20210227","first-page":"286","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study","volume":"5","author":"McKelvie","year":"1999","journal-title":"Congest Heart Fail"},{"key":"R33-4-20210227","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","article-title":"Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"R34-4-20210227","first-page":"V30","article-title":"The mortality effect of metoprolol CR\/XL in patients with heart failure: results of the MERIT-HF trial","volume":"22","author":"Goldstein","year":"1999","journal-title":"Clin Cardiol"},{"key":"R35-4-20210227","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jacc.2006.04.109","article-title":"Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial","volume":"49","author":"Anand","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R36-4-20210227","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jacc.2003.11.037","article-title":"Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study","volume":"43","author":"Rouleau","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R37-4-20210227","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.cjca.2011.07.004","article-title":"Bucindolol, systolic blood pressure, and outcomes in systolic heart failure: a prespecified post hoc analysis of BEST","volume":"28","author":"White","year":"2012","journal-title":"Can J Cardiol"},{"key":"R38-4-20210227","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ahj.2010.12.009","article-title":"Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: a complex relationship","volume":"161","author":"Ather","year":"2011","journal-title":"Am Heart J"},{"key":"R39-4-20210227","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5694\/j.1326-5377.2004.tb06178.x","article-title":"Barriers to diagnosing and managing heart failure in primary care","volume":"181","author":"Phillips","year":"2004","journal-title":"Med J Aust"},{"key":"R40-4-20210227","first-page":"615","article-title":"The barriers to effective management of heart failure in general practice","volume":"51","author":"Hickling","year":"2001","journal-title":"Br J Gen Pract"},{"key":"R41-4-20210227","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jcma.2017.04.011","article-title":"Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: results from TSOC-HFrEF registry","volume":"80","author":"Chang","year":"2017","journal-title":"J Chin Med Assoc"},{"key":"R42-4-20210227","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ejhf.510","article-title":"Physicians\u2019 adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey","volume":"18","author":"Komajda","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"R43-4-20210227","doi-asserted-by":"crossref","first-page":"e008789","DOI":"10.1161\/JAHA.118.008789","article-title":"Reasons for guideline nonadherence at heart failure discharge","volume":"7","author":"Gilstrap","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"R44-4-20210227","doi-asserted-by":"crossref","first-page":"D3","DOI":"10.1093\/ehjsupp\/4.suppl_D.D3","article-title":"Neurohormonal modulation in chronic heart failure","volume":"4","author":"Fucili","year":"2002","journal-title":"Eur Heart J Suppl"},{"key":"R45-4-20210227","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition","volume":"133","author":"Hubers","year":"2016","journal-title":"Circulation"},{"key":"R47-4-20210227","first-page":"742","article-title":"Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials","volume":"38","author":"Abdul-Rahim","year":"2017","journal-title":"Eur Heart J"},{"key":"R48-4-20210227","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"R49-4-20210227","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"R50-4-20210227","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"R51-4-20210227","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"R52-4-20210227","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/eurheartj\/ehs337","article-title":"Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies","volume":"34","author":"Pocock","year":"2013","journal-title":"Eur Heart J"},{"key":"R53-4-20210227","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCHEARTFAILURE.107.736975","article-title":"Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial","volume":"1","author":"Anand","year":"2008","journal-title":"Circ Heart Fail"},{"key":"R54-4-20210227","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/S0140-6736(17)30754-7","article-title":"Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials","volume":"389","author":"Bohm","year":"2017","journal-title":"Lancet"},{"key":"R55-4-20210227","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/HJH.0b013e32834000be","article-title":"The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials","volume":"29","author":"Czernichow","year":"2011","journal-title":"J Hypertens"},{"key":"R56-4-20210227","first-page":"127","article-title":"Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists Collaboration.","volume":"16","year":"1998","journal-title":"J Hypertens"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HJH.0000000000002094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T22:22:10Z","timestamp":1614464530000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HJH.0000000000002094"}},"subtitle":["a systematic review and meta-analysis of randomized controlled trials"],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0000000000002094","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}